MENLO PARK, CA -- (Marketwired) -- 08/01/13 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter 2013 financial results on August 8, 2013. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
To participate, dial 1-888-771-4371 from the United States or +1-847-585-4405 internationally approximately 10 minutes before the start of the call. The passcode is 35403018.
A replay will be available through August 22, 2013 at 1-888-843-7419 from the United States and
+1-630-652-3042 internationally. The passcode is 35403018.
About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. Korlym, a first generation competitive GR-II antagonist, is the company's first FDA-approved medication. The company has a phase 3 trial underway for mifepristone for treatment of the psychotic features of psychotic depression and a portfolio of selective GR-II antagonists that competitively block the effects of cortisol but not progesterone. It owns extensive intellectual property covering the use of GR-II antagonists, including mifepristone, in the treatment of a wide variety of metabolic, psychiatric and other disorders. It also holds composition of matter patents for its selective GR-II antagonists.